Turbine Showcases Virtual Cell Platform for ADC Development at Basel Conference

According to a recent LinkedIn post from Turbine, the company plans to showcase its Virtual Cells and Virtual Lab technologies at the Antibody Engineering & Therapeutics conference in Basel from May 27–29. The post notes that Business Development Director Pier Giorgio Pacifici and Senior Product Manager Ákos Tarcsay will attend, with Tarcsay scheduled to speak on antibody-drug conjugate, or ADC, development.

The post suggests that Turbine is positioning its Virtual Lab as a computational alternative to traditional trial-and-error methods in addressing resistance mechanisms and identifying synergistic payload combinations. By integrating transcriptomic, genomic, and protein–protein interaction data into virtual cell models, the company appears to be emphasizing a data-driven platform that could shorten discovery timelines and potentially lower preclinical development costs.

As described in the post, Tarcsay’s presentation will outline a virtual-cell-based screening framework for ranking and positioning payloads, synergistic partners, and ADCs, alongside automated in vitro validation and virtual gene perturbation simulations. For investors, this public focus on scalable in silico screening may indicate Turbine’s intent to expand its role as an enabling technology provider in oncology R&D, which could enhance its attractiveness for partnerships with biopharma companies.

The LinkedIn content also highlights Turbine’s ongoing business development efforts, encouraging conference attendees to connect via a dedicated email channel. This outreach may signal an active pipeline-building strategy, where increased visibility at specialized industry events could translate into new collaborations, licensing discussions, or pilot projects that influence future revenue potential.